Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRA NASDAQ:HOOK NASDAQ:SLGL NASDAQ:VBIV NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRABiofrontera$2.60$2.95$2.09▼$7.54$73.73M1.0227,512 shs7,263 shsHOOKHOOKIPA Pharma$0.93+0.2%$0.95$0.72▼$5.00$11.32M0.97115,855 shs22,673 shsSLGLSol-Gel Technologies$23.96-3.4%$16.37$4.01▼$30.00$69.11M1.2532,833 shs6,565 shsVBIVVBI Vaccines$0.23$0.06▼$1.35$1.87M2.183.66 million shs29.90 million shsWVEWAVE Life Sciences$6.97$8.49$5.28▼$16.74$1.11B-1.162.24 million shs1.26 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRABiofrontera0.00%0.00%0.00%0.00%0.00%HOOKHOOKIPA Pharma+0.17%+3.33%+11.85%-29.01%-81.36%SLGLSol-Gel Technologies-2.72%-13.05%+55.15%+232.71%+286.37%VBIVVBI Vaccines0.00%0.00%0.00%0.00%+308.13%WVEWAVE Life Sciences0.00%-8.05%-28.59%+5.77%+18.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRABiofrontera$2.60$2.95$2.09▼$7.54$73.73M1.0227,512 shs7,263 shsHOOKHOOKIPA Pharma$0.93+0.2%$0.95$0.72▼$5.00$11.32M0.97115,855 shs22,673 shsSLGLSol-Gel Technologies$23.96-3.4%$16.37$4.01▼$30.00$69.11M1.2532,833 shs6,565 shsVBIVVBI Vaccines$0.23$0.06▼$1.35$1.87M2.183.66 million shs29.90 million shsWVEWAVE Life Sciences$6.97$8.49$5.28▼$16.74$1.11B-1.162.24 million shs1.26 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRABiofrontera0.00%0.00%0.00%0.00%0.00%HOOKHOOKIPA Pharma+0.17%+3.33%+11.85%-29.01%-81.36%SLGLSol-Gel Technologies-2.72%-13.05%+55.15%+232.71%+286.37%VBIVVBI Vaccines0.00%0.00%0.00%0.00%+308.13%WVEWAVE Life Sciences0.00%-8.05%-28.59%+5.77%+18.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRABiofrontera 0.00N/AN/AN/AHOOKHOOKIPA Pharma 2.33Hold$4.50383.87% UpsideSLGLSol-Gel Technologies 0.00N/AN/AN/AVBIVVBI Vaccines 0.00N/AN/AN/AWVEWAVE Life Sciences 2.93Moderate Buy$20.33191.73% UpsideCurrent Analyst Ratings BreakdownLatest HOOK, VBIV, BFRA, SLGL, and WVE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025WVEWAVE Life SciencesB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy9/4/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.009/3/2025WVEWAVE Life SciencesLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$26.009/3/2025WVEWAVE Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.008/4/2025WVEWAVE Life SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.007/31/2025WVEWAVE Life SciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$24.00 ➝ $21.007/28/2025WVEWAVE Life SciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$24.007/16/2025WVEWAVE Life SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/23/2025WVEWAVE Life SciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$18.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRABiofrontera$36.19M2.04N/AN/A$0.35 per share7.43HOOKHOOKIPA Pharma$9.35M1.21N/AN/A$4.25 per share0.22SLGLSol-Gel Technologies$11.54M5.79N/AN/A$10.36 per share2.31VBIVVBI Vaccines$9.41M0.00N/AN/A$0.32 per share0.00WVEWAVE Life Sciences$108.30M10.24N/AN/A$1.37 per share5.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRABiofrontera-$14.88M-$0.73N/A∞N/A-59.44%-93.31%-24.02%N/AHOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%11/12/2025 (Estimated)SLGLSol-Gel Technologies-$10.58M-$1.23N/AN/AN/A-14.25%-11.80%-9.39%11/14/2025 (Estimated)VBIVVBI Vaccines-$92.84MN/A0.00N/AN/A-881.79%-525.42%-45.87%N/AWVEWAVE Life Sciences-$97.01M-$0.90N/AN/AN/AN/A-78.45%-41.51%11/11/2025 (Estimated)Latest HOOK, VBIV, BFRA, SLGL, and WVE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025SLGLSol-Gel Technologies-$0.67$4.17+$4.84$4.17$2.86 million$17.26 million7/30/2025Q2 2025WVEWAVE Life Sciences-$0.29-$0.31-$0.02-$0.31$11.52 million$8.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRABiofronteraN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/AVBIVVBI VaccinesN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRABiofrontera0.131.261.13HOOKHOOKIPA PharmaN/A3.613.61SLGLSol-Gel TechnologiesN/A7.327.32VBIVVBI VaccinesN/A0.340.21WVEWAVE Life SciencesN/A2.562.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRABiofrontera60.07%HOOKHOOKIPA Pharma63.88%SLGLSol-Gel Technologies26.18%VBIVVBI Vaccines12.26%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipBFRABiofronteraN/AHOOKHOOKIPA Pharma3.30%SLGLSol-Gel Technologies66.51%VBIVVBI Vaccines10.35%WVEWAVE Life Sciences23.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRABiofrontera13828.36 millionN/ANot OptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableSLGLSol-Gel Technologies502.79 million933,000OptionableVBIVVBI Vaccines2228.68 million25.71 millionOptionableWVEWAVE Life Sciences240159.14 million120.98 millionOptionableHOOK, VBIV, BFRA, SLGL, and WVE HeadlinesRecent News About These CompaniesWAVE Life Sciences (NASDAQ:WVE) Stock Price Down 3.5% - What's Next?September 13 at 2:11 PM | marketbeat.comWave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 StudySeptember 10, 2025 | finance.yahoo.comRaymond James Reaffirms Their Buy Rating on Wave Life Sciences (WVE)September 9, 2025 | theglobeandmail.comPolar Asset Management Partners Inc. Has $221,000 Stock Holdings in WAVE Life Sciences Ltd. $WVESeptember 9, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of WVE FY2027 EarningsSeptember 9, 2025 | marketbeat.comWave Life Sciences Announces Positive Results for WVE-006 StudySeptember 8, 2025 | theglobeandmail.comTrexquant Investment LP Sells 215,940 Shares of WAVE Life Sciences Ltd. $WVESeptember 7, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Stock Position Boosted by Invesco Ltd.September 7, 2025 | marketbeat.comB. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’September 6, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE)September 5, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Shares Gap Down - Should You Sell?September 5, 2025 | marketbeat.comWAVE Life Sciences Ltd. $WVE Shares Purchased by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Earns Buy Rating from HC WainwrightSeptember 5, 2025 | americanbankingnews.comWave Crashes Despite Successful RNA Editing in AATD StudySeptember 4, 2025 | biospace.comB683 Capital Management LLC Purchases 140,000 Shares of WAVE Life Sciences Ltd. $WVESeptember 4, 2025 | marketbeat.comJump Financial LLC Trims Stake in WAVE Life Sciences Ltd. $WVESeptember 4, 2025 | marketbeat.comWave RNA editing restores enzyme in genetic condition but underwhelms investorsSeptember 4, 2025 | fiercebiotech.comFWave shares sink on new study results for RNA editing drugSeptember 4, 2025 | finance.yahoo.comForecasting The Future: 7 Analyst Projections For WAVE Life SciencesSeptember 4, 2025 | benzinga.comWave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out WhySeptember 4, 2025 | msn.comWave Life Sciences Ltd. (WVE) Positive RestorAATion-2 Clinical Data Update Conference TranscriptSeptember 3, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHOOK, VBIV, BFRA, SLGL, and WVE Company DescriptionsBiofrontera NASDAQ:BFRABiofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.HOOKIPA Pharma NASDAQ:HOOK$0.93 +0.00 (+0.17%) As of 09/15/2025 03:39 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Sol-Gel Technologies NASDAQ:SLGL$23.96 -0.86 (-3.45%) Closing price 09/15/2025 03:59 PM EasternExtended Trading$23.96 0.00 (0.00%) As of 09/15/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.VBI Vaccines NASDAQ:VBIVVBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.WAVE Life Sciences NASDAQ:WVE$6.97 0.00 (0.00%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$6.98 +0.02 (+0.22%) As of 09/15/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
